BioLineRx Ltd.
BLRX
$3.28
-$0.06-1.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.74M | 17.25M | 22.34M | 28.94M | 21.99M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.74M | 17.25M | 22.34M | 28.94M | 21.99M |
| Cost of Revenue | 6.28M | 7.02M | 7.84M | 9.26M | 6.87M |
| Gross Profit | 6.46M | 10.23M | 14.50M | 19.68M | 15.13M |
| SG&A Expenses | 8.99M | 15.11M | 22.94M | 29.68M | 32.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.81M | 30.50M | 39.06M | 48.09M | 49.84M |
| Operating Income | -10.07M | -13.25M | -16.72M | -19.15M | -27.85M |
| Income Before Tax | -2.98M | -7.82M | -3.40M | -9.22M | -19.92M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.98 | -7.82 | -3.40 | -9.22 | -19.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.98M | -7.82M | -3.40M | -9.22M | -19.92M |
| EBIT | -10.07M | -13.25M | -16.72M | -19.15M | -27.85M |
| EBITDA | -8.37M | -10.83M | -14.00M | -15.70M | -24.99M |
| EPS Basic | 0.00 | -0.01 | 0.00 | -0.01 | -0.02 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | 0.00 | -0.01 | 0.00 | -0.01 | -0.02 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 8.50B | 7.09B | 5.92B | 4.79B | 4.56B |
| Average Diluted Shares Outstanding | 8.50B | 7.09B | 5.92B | 4.79B | 4.56B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |